New hope for Tough-to-Treat lung cancer? trial tests targeted drug combo

NCT ID NCT07336732

Recruiting now Disease control Sponsor: Avistone Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

Summary

This study is testing a new targeted drug called andamertinib, given alone or with standard chemotherapy, for adults with advanced non-small cell lung cancer. It is for people whose cancer has specific, less common genetic changes (atypical EGFR mutations) and who have not yet received treatment. The goal is to see if these new approaches can better control the cancer and are safe for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-Sen University Cancer Center
RECRUITING

Guangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER